Noe Rivera, MHA’s Post

Reflecting on success (the achievement of particular aims) at a panel discussion led by Robyn Lindner at #ausmedtech2024: ⭐️ Jerneen Williams celebrates how Bellberry, soon to celebrate its 20th anniversary, research ⭐️ Marjan Mikel noting that success is a journey and that sometimes you need to move beyond what your customers think they need to what they actually need. As your strategy evolves, you need new skills and new people. Respiri Limited ⭐️ Sam Lanyon on the ups and downs, including an unexpected FDA rejection (and it’s better to address rather than challenge their concerns!). Stay focused and be flexible! Lumos Diagnostics ⭐️ Paul Anderson on the importance of partnering well to go international, on working with brave patients to transform their lives, having a world class board to lead the organisation’s growth

🎉 Cheers to 2025! A Year of Growth, Innovation, and Opportunity 🎉 As we step into 2025, we at Oakpoint are proud to reflect on the incredible milestones we achieved together in 2024. Looking ahead, 2025 promises to be even more transformative. Our mission is clear: 🌟 Drive excellence in dental practice management. 🌟 Foster ethical leadership and sustainable growth. 🌟 Deliver unmatched value to our patients, partners, and stakeholders. To our partners, employees, and supporters—thank you for being part of this incredible journey. Together, we’ll continue to redefine what’s possible in the dental industry. 📊 Stay tuned for updates on our growth metrics, success stories, and the innovations shaping our future. Let’s make 2025 our best year yet! 🚀 #OakpointGrowth #InnovationInDentistry #EthicalLeadership #DentalExcellence #2025Goals

🚀 Exciting News from Eyebright Medical! 🚀 On October 30, Eyebright Medical (688050) disclosed its third-quarter report for 2024, and the results are impressive! 📈 In the first three quarters, we achieved: Operating Revenue: ¥1.075 billion (up 60.94% year-on-year) Net Profit Attributable to Shareholders: ¥318 million (up 26.04%) Net Profit Excluding Non-Recurring Items: ¥304 million (up 27.41%) Net Cash Flow from Operating Activities: ¥217 million (up 65.99%) 💡 This quarter, our basic earnings per share stood at ¥1.68, with a weighted average return on net assets of 14.08%. #EyebrightMedical #HealthcareInnovation #FinancialResults #Growth

Is your CI program looking for more ways to be clinically efficient? Check out our upcoming workshop series!

Today marks an exciting new chapter in our company’s history – completion of transformational merger between The X-Ray Group's parent company, Integral Diagnostics (IDX) and Capitol Health. The integration of our two companies is a powerful step toward realising our shared vision for growth, innovation, and the ongoing provision of diagnostic imaging in our local communities. The merge makes us the second largest private imaging provider in Australasia! Exciting times for our teams, patients, referrers, partners and suppliers but for now, it is business as usual with no changes to patient care or our operations. Business as usual at The X-Ray Group - all operations will remain unchanged. Our quality of care to patients and referrer support will continue to be our focus. You can read more here: https://lnkd.in/gbtncPM3

How does an organization compete in a massively consolidated industry? That was one of the topics Capital Rx's co-founder & CEO A. J. Loiacono discussed while attending an HLTH USA panel -- "Owning the Boardwalk." Joining Dr. Robert Pearl, M.D., Randi Seigel, Elizabeth Jurinka , and moderator Seth Joseph, AJ broke down how he's successfully grown businesses amidst difficult circumstances, why #pharmacyclaimsprocessing is broken, and how building JUDI® presents an aligned, cost-effective, and future proof path forward for #planfiduciaries. Click here to check out some highlights from the panel: https://okt.to/eEiyBp

Bright future ahead for Nymbl Systems

That’s it for #MTC24! Key Takeaways for Wellumio. • Series A fundraising remains the most challenging at the moment, but the venture market is showing signs of opening up, with growing optimism. • The Cerebel IPO is a positive signal that exits are back on the table (maybe). • Corporate strategics are open to M&A opportunities with varying strategies. Great to see the neurovascular market experiencing high growth. • Traditional hardware vendors are shifting away from simply selling boxes but offering comprehensive solutions to address problems. We must remain solution focused. • There’s been a noticeable European absence, while APAC is emerging as a significant market opportunity. • Home hospital care, which gained momentum during COVID-19, presents a potential opportunity for portable medical devices. Other learnings to come. With so many concurrent sessions, it was great to have our new US-based Vice President of Product Development, Daniel Weyers attend, allowing us to be in two places at once. Daniel recently joined the team after 8 years at GE HealthCare where he was Global Product Manager RF Coils. We are looking forward to the journey ahead! #medtechcon

Today marks an exciting new chapter in our company’s history – completion of a transformational merger between Capitol Health and Integral Diagnostics (IDX)! The integration of our two companies is a powerful step toward realising our shared vision for growth, innovation, and the ongoing provision of diagnostic imaging in our local communities. The merge makes us the second largest private imaging provider in Australasia! Exciting times for our teams, patients, referrers, partners and suppliers but for now, it is business as usual with no changes to patient care or our operations. Read more here: https://lnkd.in/gwCNgGGV

How does an organization compete in a massively consolidated industry? That was one of the topics Capital Rx's co-founder & CEO A. J. Loiacono discussed while attending an HLTH USA panel -- "Owning the Boardwalk." Joining Dr. Robert Pearl, M.D., Randi Seigel, Elizabeth Jurinka , and moderator Seth Joseph, AJ broke down how he's successfully grown businesses amidst difficult circumstances, why #pharmacyclaimsprocessing is broken, and how building JUDI® presents an aligned, cost-effective, and future proof path forward for #planfiduciaries. Click here to check out some highlights from the panel: https://okt.to/1XUW0C